Biotech

BELLUS Health Inc. a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that three abstracts on BLU-5937 have been accepted for presentation at the upcoming American Thoracic Society 2021 International Conference, being held on May 14-19, 2021. Mini Symposium Presentation: Title: ...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that three abstracts on BLU-5937 have been accepted for presentation at the upcoming American Thoracic Society ("ATS") 2021 International Conference, being held on May 14-19, 2021.

Mini Symposium Presentation:

Title: Improvements in Cough Frequency Over 24 Hours with BLU-5937, a Selective P2X3 Antagonist, in Patient Subgroups Defined by Baseline Awake Cough Frequencies Session: Hot Takes from Clinical Trials in Lung Disease (A006) Format: Pre-recorded presentation and live discussion period Date: Sunday, May 16 Time: 10:00 11:30 a.m. EDT

Poster Presentations:

Title: Design of SOOTHE, a Phase 2b Dose Finding Study with BLU-5937, a Selective P2X3 Antagonist, in Refractory Chronic Cough
Session: Assessment and Treatment of Cough and Chronic Dyspnea (TP044)
Format: On demand

Title: Baseline Characteristics and Burden of Disease in Populations Defined by Cough Frequency Tiers in RELIEF, a Phase 2 Study on the Efficacy and Safety of BLU-5937 in Refractory Chronic Cough
Session: Assessment and Treatment of Cough and Chronic Dyspnea (TP044)
Format: On demand

Following the conference, the presentation materials will be available in the "Scientific Publications" section of BELLUS Health's website at www.bellushealth.com .

About BELLUS Health ( www.bellushealth.com )

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of RCC and chronic pruritus associated with AD.

RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and current treatment options are limited.

Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated that up to 10% of adults in the United States suffer from AD – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting AD, there continues to be a lack of options targeting the burden of pruritus in patients with AD.

Forward-Looking Statements

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the meaning of Canadian securities legislation and regulations, the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potential," "possible," "projects," "plans," and similar expressions. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond BELLUS Health's control. Such statements include, but are not limited to, the potential of BLU-5937 to successfully treat chronic cough, chronic pruritus and other hypersensitization-related disorders, BELLUS Health's expectations related to its preclinical studies and clinical trials, including the design and timing of its Phase 2b clinical trial of BLU-5937 in RCC and its Phase 2 clinical trial of BLU-5937 in chronic pruritus associated with AD, including the timing and outcome of interactions with regulatory agencies, the potential activity and tolerability profile, selectivity, potency and other characteristics of BLU-5937, including as compared to other competitor candidates, the commercial potential of BLU-5937, including with respect to patient population, pricing and labeling, BELLUS Health's financial position, and the potential applicability of BLU-5937 and BELLUS Health's P2X3 platform to treat other disorders. Risk factors that may affect BELLUS Health's future results include but are not limited to: the benefits and impact on label of its enrichment strategy, estimates and projections regarding the size and opportunity of the addressable RCC market for BLU-5937, the ability to expand and develop its project pipeline, the ability to obtain adequate financing, the ability of BELLUS Health to maintain its rights to intellectual property and obtain adequate protection of future products through such intellectual property, the impact of general economic conditions, general conditions in the pharmaceutical industry, the impact of the COVID-19 pandemic on BELLUS Health's operations, plans and prospects, including to the initiation and completion of clinical trials in a timely manner or at all, changes in the regulatory environment in the jurisdictions in which BELLUS Health does business, stock market volatility, fluctuations in costs, changes to the competitive environment due to consolidation, achievement of forecasted burn rate, potential payments/outcomes in relation to indemnity agreements and contingent value rights , achievement of forecasted preclinical study and clinical trial milestones, reliance on third parties to conduct preclinical studies and clinical trials for BLU-5937 and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. In addition, the length of BELLUS Health's product candidate's development process and its market size and commercial value are dependent upon a number of factors. Moreover, BELLUS Health's growth and future prospects are mainly dependent on the successful development, patient tolerability, regulatory approval, commercialization and market acceptance of its product candidate BLU-5937 and other products. Consequently, actual future results and events may differ materially from the anticipated results and events expressed in the forward-looking statements. BELLUS Health believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward-looking statements speak only as of the date made, and BELLUS Health is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see BELLUS Health's public filings with the Canadian securities regulatory authorities, including, but not limited to, its Annual Information Form, and the United States Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 40-F, for further risk factors that might affect BELLUS Health and its business.

Danny Matthews
Director, Investor Relations and Communications
danny@bellushealth.com

Media:
Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com

News Provided by Business Wire via QuoteMedia

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Results suggest broader applications for DehydraTECH-CBD beyond hypertension

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECHTM-processed cannabidiol ("CBD") reduces arterial stiffness, potentially broadening its application to treatment of cardiovascular and other disease states beyond hypertension where it has already shown tremendous promise

Keep reading... Show less
Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

(TheNewswire)

Lexaria Bioscience Corp.

Results suggest broader applications for DehydraTECH-CBD beyond hypertension

Keep reading... Show less
BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant

BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant

  • Cannabis produced has a Trichomes density of up to 200 times greater than in a plant-grown product while solving major industry challenges of consistency, safety, and environmental sustainability
  • The Company is ready to engage with key players in the global Cannabis industry

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") has announced that it has produced a meaningful amount (10 kilograms) of full-spectrum Cannabis biomass at a commercial scale without growing the plant itself. (For full illustration, watch the "Cannabis Without Plants - History in the Making" video at https:youtu.beNAurl6oa1xo)

Keep reading... Show less
Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference

Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference

Lexaria Bioscience Corp. (NASDAQ: LEXX) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space.

Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/december-2021-global/.

Keep reading... Show less

Amgen Announces New Data Being Presented At ASH 2021

- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia and virtually, from Dec. 11-14, 2021 .

"The data being presented at ASH demonstrates Amgen's commitment to reaching more patients with our innovative hematology medicines and improving the patient experience by exploring more convenient administrations for people living with blood cancers," said David M. Reese , M.D., executive vice president of Research and Development at Amgen. "By accelerating the development and delivery of transformative medicines in difficult to treat and vulnerable patient populations, including children and pregnant women, we continue to focus on the relentless pursuit of breakthroughs for blood cancer patients and their families."

Keep reading... Show less

Upadacitinib Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease

ABBVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission a,b and endoscopic response c at week 12. 1 The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60 percent having previously failed two or more biologics. 1 U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. 1

"The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino , M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."

Keep reading... Show less

Top News

Related News